Coronavirus: Bharat Biotech gets approval to conduct human trials for vaccine

Clay Curtis
July 1, 2020

China's military has approved a coronavirus vaccine for use within its ranks.

In May 2020, Bharat Biotech went into a partnership with Thomas Jefferson University, Philadelphia, for an exclusive deal to develop a new vaccine candidate for COVID-19 that was invented at Jefferson.

China is just one of several countries rushing to produce a vaccine for the novel coronavirus, which has now infected more than 10.3 million people worldwide and killed at least 505,000. A vaccine has to prove its effectiveness in "Phase 3" human test where thousands of participants are recruited in order to be cleared for sale.

The pre-clinical data suggest that the vaccine is safe and effective to use on humans.

So far, Moderna leads the U.S. race to make a coronavirus shot.

Scientists across the globe are now working towards a vaccine faster than ever.

TikTok goes offline in India, alert says ‘complying with government directive’
Since the latest clash, the nuclear-armed neighbours have reinforced the border between Ladakh and Tibet. The move comes after violent border skirmishes killed at least 20 Indian soldiers in Galwan.

As COVID-19 continues to rampage across the globe, Brazil stands alongside the the countries hardest hit with new infections and deaths. But many people believe a vaccine initially would be made available through a much lower standard for temporary approvals, through what's called an emergency use authorization. Another four or five home-grown vaccines are in early stages of development. Catalent is already in partnership with Johnson and Johnson as well as AstraZeneca.

Ironically, the breakneck pace of development through the United States government program has inspired wariness, rather than confidence, among Americans.

None have yet been approved for commercial use against the coronavirus.

In response to another poll, 70 percent of people in the USA who said they would not get a coronavirus shot if it were available today (who accounted for about half of respondents) cited safety concerns. If it emerges successful, we may have a vaccine at the end of this year. That's the key, ' Ezekiel Emanuel, chair of the department of medical ethics and health policy at University of Pennsylvania and health adviser to Democratic presidential candidate Joe Biden told Politico. That authorization was recently revoked after trials showed it was ineffective and the FDA got reports of heart problems caused by the drug.

The company says that the formula; known as Ad5-nCoV, is now limited to use by military personnel, and can not be offered to a broader population without the approval of the Logistics Support Department, the division of the Central Military Commission which approved the military use of the vaccine.

Other reports by

Discuss This Article